# Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

> **NCT00387374** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 72 (actual)

## Conditions studied

- Adenosquamous Cell Lung Cancer
- Drug/Agent Toxicity by Tissue/Organ
- Hemoptysis
- Squamous Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00387374
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387374, "Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00387374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*